← All trials
NCT06705192
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2024
- Primary completion
- Jun 23, 2025
- Completion date
- Aug 5, 2025
- First posted
- Nov 26, 2024
- Last posted
- Dec 3, 2024
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vesper Biotechnologies ApSLead sponsor
- Vesper Biotechnologies ApSOfficial
- Vesper Biotechnologies ApSSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.